RBV Capital

Botkin.AI is a software-based platform for medical image processing and analysis based on artificial intelligence. The Company provides AI for analyzing radiograms and diagnosing the risk of tumors. The solution is based on deep machine learning. Botkin.AI significantly expands the radiologists’ ability to diagnose tumors and speeds up the processing of an increased flow of the patient’s clinical data without losing the quality of medical conclusions. It was founded in 2015 and is based in Moscow, Russian.

IAG, imaging expert company helps to accelerate novel drug development by using the right analytical tools and modern trial infrastructure. This includes bringing AI, Machine Learning and smart image analysis methods to ensure the speed and cost-effectiveness, while delivering true insights about your mechanism of action and patients’ response, in real-time.

Pipeline Therapeutics Inc. develops and commercializes small molecules for neuroregeneration, including synaptogenesis, remyelination, and axonal repair. The company’s lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy. The company also has a portfolio of earlier stage programs, including PIPE-307, focused on remyelination and axonal repair to address a range of neurological disorders, including multiple sclerosis. The company was founded in 2017 and is based in San Diego, California.

Bonti, Inc., a biotechnology company, develops neurotoxin products for aesthetic and therapeutic applications. It develops botulinum neurotoxin serotype E (BoNT/E), EB-001A (aesthetic), and EB-001T (therapeutic). The company was formerly known as Endurance Biotech, Inc. and changed its name to Bonti, Inc. in August 2015. Bonti, Inc. was incorporated in 2015 and is based in Newport Beach, California. As of October 24, 2018, Bonti, Inc. operates as a subsidiary of Allergan plc.

RetroSense Therapeutics is a biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved drugs to improve or restore vision in patients with these retinal degenerative conditions. The company's approach to using optogenetics in vision restoration is based on pioneering, proprietary research conducted at Wayne State University and Massachusetts General Hospital. Founded in 2009, RetroSense Therapeutics is headquartered in Ann Arbor, Michigan.

Botkin.AI is a software-based platform for medical image processing and analysis based on artificial intelligence. The Company provides AI for analyzing radiograms and diagnosing the risk of tumors. The solution is based on deep machine learning. Botkin.AI significantly expands the radiologists’ ability to diagnose tumors and speeds up the processing of an increased flow of the patient’s clinical data without losing the quality of medical conclusions. It was founded in 2015 and is based in Moscow, Russian.

Pipeline Therapeutics Inc. develops and commercializes small molecules for neuroregeneration, including synaptogenesis, remyelination, and axonal repair. The company’s lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy. The company also has a portfolio of earlier stage programs, including PIPE-307, focused on remyelination and axonal repair to address a range of neurological disorders, including multiple sclerosis. The company was founded in 2017 and is based in San Diego, California.

Immusoft Corporation operates as a biotechnology company that develops an autologous cell therapy platform for treating various human diseases through its Immune System Programming (ISP) technology. The company develops protein therapeutics using a patient's cells. Its technology enables the in vivo delivery of gene-encoded medicines (biologics) by re-programming the patient’s cells to replace missing or defective enzymes and proteins. The company was founded in 2009 and is based in Seattle, Washington.